From Zacks: Biotech stocks have been under intense pressure for more than a year now with sector-specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario weighing on the sector.
However, the sector’s fundamentals remain strong — mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.
Drug Pricing to Remain in Focus